Federal Circuit Affirms Ruling On Prilosec Process

Law360, New York (April 23, 2007, 12:00 AM EDT) -- An appeals court on Monday affirmed a district court’s ruling that generic maker Andrx Pharmaceuticals Inc. infringed on claims of AstraZeneca LP’s patent for its gastric acid-inhibiting drug, Prilosec, and affirmed that the same patent was invalid.

Despite appeals from Andrx, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling on two phases of the lengthy suit, issued by the court in August 2004.

Although the whole case involved several patents, various defendants...
To view the full article, register now.